From Naiot Venture Accelerator to Acquisition by Boston Scientific, Remon Medical Technologies Stays Ahead of the Curve
 |
Remon Medical Technologies is an innovator in designing, developing, and commercializing miniaturized implant devices that enable wireless communication, monitoring and activation deep within the body. Remon has a platform technology applicable in many areas. Its primary focus is on the cardiology and vascular surgery markets. |
The Remon ImPressureTM, Remon's flagship product, is an advanced miniature implant that enables physicians to assess and treat Congestive Heart Failure (CHF) patients in a non-invasive manner. Remon's unique technology utilizes wireless communications to activate its tiny devices acoustically. When placed deep inside the body, the implants monitor a variety of physiological parameters, stimulate tissues and organs, or activate other devices, creating therapeutic responses. The system completes the therapy feedback process by identifying high-risk patients for therapy adjustment to prevent hospitalization, and thereby, cut reduce costs .
Milestones:
| 1997 |
Remon Medical Technologies is founded by Dr. Yariv Porat and Yossi Tzaliach and, together with Dr. Eyal Doron, joins Naiot venture accelerator.
|
| 1999 |
Remon raises $3 M in Series A round, co-led by Concord Ventures and Biomedical vestments Ltd.
|
| 2001 |
Polaris Venture Partners leads a $10 M Series B round of funding for Remon Medical Technologies, along with its previous investors.
|
| 2004 |
The company raises $26 Million in Series C financing, led by Lilly Ventures and KBL Healthcare Venture, together with Polaris Venture Partners, Concord, Triathlon Medical Ventures and Medica Venture Partners, joined by new investor, the Ofer Hi-Tech Group.
Remon enters into a co-development and supply agreement with
Guidant Corporation, later acquired by Boston Scientific. |
| 2007 |
Boston Scientific Corporation announces definitive agreement to acquire Remon Medical Technologies Inc.
|
"Naiot played key role in the development of Remon at its early stage", says CEO Hezi Himelfarb. “The Naiot team helped us form and present our first feasibility study and get initial support from OCS. We are very grateful for their initial support and guidance".
As for the future, says Himelfarb: "Once integrated into the Boston Scientific products portfolio, the acquisition will position Remon as a recognized leader in intra-body wireless communication and help realize the full potential of our technology". Boston Scientific Executive Vice President, Operations and Technology, CRM, and Chief Technology Officer Fred Colen confirms:
"Remon Medical Technologies brings to Boston Scientific innovative sensor and wireless communication technology, which complements our Cardiac Rhythm Management product line."
"
